No Data
Bicara Therapeutics Says Updated Data From Ongoing Phase 1/1b Clinical Trial Of Ficerafusp Alfa In 1L R/M HNSCC To Be Highlighted In Oral Presentation At 2025 ASCO Annual Meeting
Wells Fargo Initiates Bicara Therapeutics(BCAX.US) With Sell Rating, Announces Target Price $8
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $44
Express News | HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44